194 related articles for article (PubMed ID: 10710827)
1. Review--antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach.
Gionchetti P; Rizzello F; Venturi A; Ugolini F; Rossi M; Brigidi P; Johansson R; Ferrieri A; Poggioli G; Campieri M
Eur Rev Med Pharmacol Sci; 1999; 3(1):27-30. PubMed ID: 10710827
[TBL] [Abstract][Full Text] [Related]
2. Rifaximin in the treatment of inflammatory bowel disease.
Guslandi M
World J Gastroenterol; 2011 Nov; 17(42):4643-6. PubMed ID: 22180705
[TBL] [Abstract][Full Text] [Related]
3. Management of inflammatory bowel disease: does rifaximin offer any promise?
Gionchetti P; Rizzello F; Morselli C; Romagnoli R; Campieri M
Chemotherapy; 2005; 51 Suppl 1():96-102. PubMed ID: 15855753
[TBL] [Abstract][Full Text] [Related]
4. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases.
Sartor RB
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():27-36. PubMed ID: 26618923
[TBL] [Abstract][Full Text] [Related]
5. Role of antibiotics for treatment of inflammatory bowel disease.
Nitzan O; Elias M; Peretz A; Saliba W
World J Gastroenterol; 2016 Jan; 22(3):1078-87. PubMed ID: 26811648
[TBL] [Abstract][Full Text] [Related]
6. Role of Rifaximin in Inflammatory Bowel Disease Treatment.
Scribano ML
Mini Rev Med Chem; 2015; 16(3):225-9. PubMed ID: 26202194
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiota and inflammatory bowel disease: the role of antibiotics in disease management.
Kerman DH; Deshpande AR
Postgrad Med; 2014 Jul; 126(4):7-19. PubMed ID: 25141239
[TBL] [Abstract][Full Text] [Related]
8. [Clinical and pharmacological aspects of rifaximin, local antibiotic therapy in intestinal disorders].
Gasztonyi B; Hunyady B
Orv Hetil; 2004 Oct; 145(43):2177-81. PubMed ID: 15575494
[TBL] [Abstract][Full Text] [Related]
9. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobials in the management of inflammatory bowel disease.
Gionchetti P; Rizzello F; Lammers KM; Morselli C; Tambasco R; Campieri M
Digestion; 2006; 73 Suppl 1():77-85. PubMed ID: 16498255
[TBL] [Abstract][Full Text] [Related]
11. Rifaximin: a nonabsorbed oral antibiotic.
Baker DE
Rev Gastroenterol Disord; 2005; 5(1):19-30. PubMed ID: 15741929
[TBL] [Abstract][Full Text] [Related]
12. Rifaximin for inflammatory bowel disease.
Guslandi M
Dig Dis Sci; 2010 Jun; 55(6):1805. PubMed ID: 20428944
[No Abstract] [Full Text] [Related]
13. Antibiotics and probiotics in inflammatory bowel disease: why, when, and how.
Prantera C; Scribano ML
Curr Opin Gastroenterol; 2009 Jul; 25(4):329-33. PubMed ID: 19444096
[TBL] [Abstract][Full Text] [Related]
14. Antibiotics for inflammatory bowel disease: do they work?
Guslandi M
Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):145-7. PubMed ID: 15674090
[TBL] [Abstract][Full Text] [Related]
15. Antibiotics and probiotics in treatment of inflammatory bowel disease.
Gionchetti P; Rizzello F; Lammers KM; Morselli C; Sollazzi L; Davies S; Tambasco R; Calabrese C; Campieri M
World J Gastroenterol; 2006 Jun; 12(21):3306-13. PubMed ID: 16733845
[TBL] [Abstract][Full Text] [Related]
16. Role of antibiotics in the management of inflammatory bowel disease: a review.
Rubin DT; Kornblunth A
Rev Gastroenterol Disord; 2005; 5 Suppl 3():S10-5. PubMed ID: 17713454
[TBL] [Abstract][Full Text] [Related]
17. Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases.
Schultz M; Schölmerich J; Rath HC
Dig Dis; 2003; 21(2):105-28. PubMed ID: 14571109
[TBL] [Abstract][Full Text] [Related]
18. Practical Considerations and the Intestinal Microbiome in Disease: Antibiotics for IBD Therapy.
Fedorak RN; Ismond KP
Dig Dis; 2016; 34(1-2):112-21. PubMed ID: 26982586
[TBL] [Abstract][Full Text] [Related]
19. New trends in non-absorbable antibiotics in gastrointestinal disease.
Di Febo G; Calabrese C; Matassoni F
Ital J Gastroenterol; 1992; 24(9 Suppl 2):10-3. PubMed ID: 1486193
[TBL] [Abstract][Full Text] [Related]
20. Use of rifaximin in gastrointestinal and liver diseases.
Shayto RH; Abou Mrad R; Sharara AI
World J Gastroenterol; 2016 Aug; 22(29):6638-51. PubMed ID: 27547007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
